Serum immunoglobulin E is associated with glycated hemoglobin in human with diabetic mellitus

Paper Details

Research Paper 01/09/2012
Views (239) Download (13)
current_issue_feature_image
publication_file

Serum immunoglobulin E is associated with glycated hemoglobin in human with diabetic mellitus

Parsian Heshmatolah, Faraji Gholamreza, Zand Alireza, Imanzadeh Reza
J. Bio. Env. Sci.2( 9), 80-85, September 2012.
Certificate: JBES 2012 [Generate Certificate]

Abstract

Recent evidence suggests the importance of molecules secreted by mast cell in diabetes. This study’s purpose was to determine whether serum Immunoglobulin E is associated with glycated hemoglobin and insulin resistance in human with diabetic mellitus. For this purpose, fasting serum Immunoglobulin E, glycated hemoglobin and insulin resistance were measured in forty five sedentary adult males (age 41±6 yrs, body weight 95±12 Kg) with diabetic mellitus. Pearson correlation coefficients were used to determine the associations between IgE with HbA1C and insulin resistance. A p-value less than 0.05 were considered statistically significant. A significant positive correlation was found between serum Immunoglobulin E with glycated hemoglobin (P= 0.000, r = 0.68). Serum Immunoglobulin E was also correlated positively with insulin resistance in studied patients (P= 0.000, r = 0.56). Based on high correlation in IgE with insulin resistance and HbA1C, It can be concluded that mast cell– related molecules can be affect pre-diabetes and diabetes mellitus, although more research is needed to further explore the physiopathological mechanisms underlying these associations.

VIEWS 7

Alwan AAS. 1994. Managements of diabetes mellitus standards of care and clinical practice guideline. Word health organization regional office for the eastern Mediterranean. 1, 1-35.

Anupama N, Vishnu Sharma M, Nagaraja HS. 2005. Ramesh BhatThe serum immunoglobulin E level reflects the severity of bronchial asthma. American review of respiratory disease 18 (3), 35-40.

Bergman RN, Ader M, Huecking K, Van Citters G. 2002. Accurate assessment of β-cell function: the yperbolic correction. Diabetes 51, 212– 220.

Bergman RN, Finegood DT, Kahn SE. 2002. The evolution of β-cell dysfunction and insulin resistance in type 2 diabetes. Eur J Clin Invest 32, 35–45.

Bradding P, Walls AF, Holgate ST. 2006. The role of the mast cell in the pathophysiology of asthma. J Allergy Clin Immunol 117: 1277–1284.

Bureau F. 2010. Management of Diabetes. Prisons Clinical Practice Guidelines. 3, 10-48.

Eizadi M, Bakhshi S, Abrifam P, Khorshidi D. 2011. Does systemic inflammation and allergen-specific IgE are related to each other in presence asthma. International Journal of Biosciences 1(5), 89-94.

Erdogan O, Altun A, Gul C, Ozbay G. 2003. C-reactive protein and immunoglobulin-E response to coronary artery stenting in patients with stable angina. Jpn Heart J 44, 593–600.

Goodarzi MT, Babaahmadi-Rezaei H, Kadkhodaei-Eliaderani M, Haddadinezhad S. 2007. Relationship of serum adiponectin with blood lipids, HbA(1)c, and hs-CRP in type II diabetic postmenopausal women. J Clin Lab Anal 21(3), 197-200.

heoharides TC, Kalogeromitros D. 2006. The critical role of mast cells in allergy and inflammation. Ann N Y Acad Sci 1088, 78–99.

Ishizaka T, Ishizaka K. 1984. Activation of mast cells for mediator release through IgE receptors. Prog Allergy 34(2) 188-235.

Liu J, Divoux A, Sun J, Zhang J, Cle ´ment K. 2009. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. Nat Med 15, 940–945.

Pate MB, Smith JK, Chi DS, Krishnaswamy G. 2010. Regulation and dysregulation of immunoglobulin E: a molecular and clinical perspective. Clin Mol Allergy 8, 3.

Putz DM, Goldner WS, Bar RS, Haynes WG, Sivitz WI. 2004. Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy. Metabolism 53(11), 1454-61.

Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE. 2002. Defining the relationship between plasma glucose and HbA1c: analysis of glucose profiles and HbA1c in the Diabetes Control and Complications trial. Diabetes Care 25, 275–278

Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. 2005. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med 165, 1910– 1916.

Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett AR. 2005. Glycemia (haemoglobin A1c) and incident of ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) study. Lancet Neurol 4, 821–826.

Shatat IF, Freeman KD, Vuguin PM, Dimartino-Nardi JR, Flynn JT. 2009. Relationship between adiponectin and ambulatory blood pressure in obese adolescents. Pediatr Res 65(6), 691-5.

Wang Z, Zhang H, Shen XH, Jin KL, Ye GF. 2011. Immunoglobulin E and Mast Cell Proteases Are Potential Risk Factors of Human Pre-Diabetes and Diabetes Mellitus. Ann Med 6(12), 28962.

Weyer C, Bogardus C, Mott DM, Pratley RE. 1999. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104, 787–794.

Winter WE, Hardt NS, Fuhrman S. 2000. Immunoglobulin E, importance in Parasitic Infections and Hypersensitivity Responses. Archives of Pathology & Laboratory Medicine 124(9), 1382-5.